Viagra ‘should be tested as Alzheimer’s therapy’
pharmaphorum
DECEMBER 7, 2021
That finding could provide some comfort to Biogen and Eisai, whose recently-approved amyloid-targeting drug Aduhelm (aducanumab) is struggling to gain traction in the market on the back of unconvincing efficacy data, safety concerns and a high price tag.
52 
Let's personalize your content